HOME >> BIOLOGY >> NEWS
Vaccinating wildlife can reduce human risk for Lyme disease

Direct field evidence shows that Lyme disease in humans can be prevented by vaccinating wildlife, researchers in the Department of Epidemiology and Public Health at Yale School of Medicine report in the Proceedings of the National Academy of Sciences.

In a four-year study of isolated woodlands near New Haven, nearly 1,000 white-footed mice were trapped and either vaccinated against Lyme disease or given a placebo. Fewer deer ticks tested positive for Lyme disease in the experimental plots where mice had been vaccinated. Fewer ticks carrying infection reduced the risk for humans getting Lyme disease from a tick bite.

"Vaccinating wildlife increases our prevention options," said principal investigator Durland Fish, professor of epidemiology at Yale, who led the study with Jean Tsao, now at Michigan State University and microbiologist Alan Barbour at University of California at Irvine. "Despite a record increase in cases, efforts to prevent Lyme disease with a human vaccine were set back in 2002 when it was pulled from the market due to poor sales."

Although the study showed significant reduction in risk and was the first demonstration of a wildlife vaccination effect for any vector-borne disease, the reduction was not as great as the investigators had hoped.

A surprising result was that mice are not as important in maintaining the Lyme disease bacterium in nature as previous studies showed. "If only mice were responsible for infecting the ticks, we would have seen a much greater reduction," Fish explained. "We now believe that mice are responsible for only 27 to 55 percent of the infection found in ticks. This changes our view on how Lyme disease is circulated between wildlife and ticks."

Fish said that in addition to mice, other animals must receive Lyme disease vaccination in order to further reduce risk to humans. Oral vaccines, similar
'"/>

Contact: Karen N. Peart
karen.peart@yale.edu
203-432-1326
Yale University
13-Dec-2004


Page: 1 2

Related biology news :

1. The new wildlife refuge -- Golf courses?
2. Manipulating nature: Scientists query wildlife birth-control method
3. Study questions the biodiversity hotspot approach to wildlife conservation
4. Research highlights how farmers agri-environment schemes could do more for wildlife
5. High-tech equipment may help reduce wildlife-vehicle collisions
6. Moving wildlife detrimental to oral rabies vaccination project
7. UGA researchers find that hunting can increase the severity of wildlife disease epidemics
8. Report: Canadas Yellowstone too small for wildlife
9. Afghanistan to protect wildlife and wild lands
10. Test for dioxin sensitivity in wildlife could result from new study
11. Monkey-dung study offers clues about land-use, wildlife ecology

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Vaccinating wildlife can reduce human risk for Lyme disease

(Date:2/13/2015)... , Feb. 13, 2015 ACT ... company that aims to transform cancer genomic information ... that the company has raised US$ 8 million in ... Based in Taipei, Taiwan , ... ACTDrug™, ACTOnco™. With the aim to implement next ...
(Date:2/9/2015)... RICHARDSON, Texas , Feb. 9, 2015  Lintec ... novel fabrication methods for carbon nanotube (CNT) macrostructures, including ... Texas at Dallas (UTD). Leveraging the vast ... Tokyo, Japan , Lintec of America ... Richardson, TX , focusing on scaling ...
(Date:2/5/2015)... 2015   Marvin Test Solutions , ... test solutions for military, aerospace, and manufacturing ... TS-323 GENASYS Test Platform to ... is a high-performance PXI-based system designed to ... require performance functional testing. GENASYS features a ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
(Date:2/28/2015)... 2015 Increasing its efforts to resolve the ... first three episodes of The GMO TRUTH podcast on both ... as it continues its mission to discover the truth and ... phase, to “uncover the truth about the GMOs in our ... GMO Truth Podcast is an expansion of the documentary/investigative film-making ...
(Date:2/27/2015)... Calif. , Feb. 27, 2015  Pharmacyclics, ... that longer-term toxicology studies for its newly developed ... or RA, have been completed. The results of ... U.S. Food and Drug Administration. The feedback received ... of the ongoing first-in-human study. Additional preclinical work ...
(Date:2/27/2015)... Halifax, Nova Scotia (PRWEB) February 27, 2015 ... clinical stage vaccine and immunotherapy company, today announced ... approved its application for Fast Track designation and ... DPX-Ebola vaccines, in conjunction with the mutual co-development ... had previously obtained Fast Track designation for the ...
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE ... development of biosimilar therapeutics, today announced that it will ... Marriott Marquis on March 2 nd at 3pm ... on a panel discussing the current state of the ... Biosimilars . For more information on ...
Breaking Biology Technology:The Walk a Mile Project Launches “GMO Truth” Podcast 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3
Cached News: